Details of Disease

General Information of Disease (ID: DISAW5MD)

• Disease Name: Uterine serous carcinoma
• Synonyms: uterine corpus serous adenocarcinoma; uterine serous adenocarcinoma; uterine serous carcinoma; uterine papillary serous carcinoma; endometrial serous adenocarcinoma; uterine serous papillary adenocarcinoma; serous endometrial adenocarcinoma
• Disease Class: 2C72: Uterine ligament/parametrium/uterine adnexa neoplasm
• Definition: A high grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.
• Disease Hierarchy:
  DISYL50L: Serous adenocarcinoma
  DISAW5MD: Uterine serous carcinoma
• ICD Code: ICD-11: ICD-11: 2C72.1
• Disease Identifiers:
  MONDO ID: MONDO_0006196
  UMLS CUI: C0854924
  MedGen ID: 1659908

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ZN-c3	DM4MSLY	Phase 2	Small molecular drug	[1]
SYN125	DM4UVTO	Phase 1	Antibody	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AURKB	TT9RTBL	Strong	Biomarker	[3]
CCNE1	TTCEJ4F	Strong	Biomarker	[4]
LSS	TT7O8ZA	Strong	Biomarker	[5]
SNCG	TT5TQNZ	Strong	Biomarker	[6]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CDC42SE2	OT8SG9I1	Strong	Biomarker	[7]
ERGIC2	OT3MEGIU	Strong	Biomarker	[8]
NEU1	OTH9BY8Y	Strong	Biomarker	[9]
NEURL1	OT2C4P70	Strong	Biomarker	[9]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[10]

References

• [1] ClinicalTrials.gov (NCT04814108) A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04363242) A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body.. U.S. National Institutes of Health.
• [3] Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.
• [4] Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.
• [5] Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Mllerian serous carcinomas: clinical divergence without immunophenotypic differences.Gynecol Oncol. 2000 Dec;79(3):430-7. doi: 10.1006/gyno.2000.6000.
• [6] Synuclein- in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.Cancer. 2017 Apr 1;123(7):1144-1155. doi: 10.1002/cncr.30477. Epub 2016 Dec 7.
• [7] Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.Clin Cancer Res. 2000 Jan;6(1):278-84.
• [8] Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel.Oncotarget. 2018 Aug 10;9(62):31985-31998. doi: 10.18632/oncotarget.25868. eCollection 2018 Aug 10.
• [9] Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.Tumour Biol. 2015 Jul;36(7):5505-13. doi: 10.1007/s13277-015-3218-4. Epub 2015 Feb 11.
• [10] Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.J Pathol. 2011 May;224(1):1-4. doi: 10.1002/path.2884. Epub 2011 Mar 22.